{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:16:54Z","timestamp":1792721814351,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA254342"],"award-info":[{"award-number":["R01CA254342"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["T2023-018"],"award-info":[{"award-number":["T2023-018"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["T32 CA121938"],"award-info":[{"award-number":["T32 CA121938"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.trecan.2025.12.008","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:12:21Z","timestamp":1772885541000},"page":"358-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Disarming cancer resistance: FAK as a therapeutic target"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-3169","authenticated-orcid":false,"suffix":"III","given":"Terrance J.","family":"Haanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-9210","authenticated-orcid":false,"given":"David D.","family":"Schlaepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.12.008_bb0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/358690a0","article-title":"Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation","volume":"358","author":"Guan","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.12.008_bb0010","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1073\/pnas.89.11.5192","article-title":"pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions","volume":"89","author":"Schaller","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.12.008_bb0015","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.89.18.8487","article-title":"Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin","volume":"89","author":"Hanks","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.12.008_bb0020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1242\/jcs.00373","article-title":"Focal adhesion kinase: the first ten years","volume":"116","author":"Parsons","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0030","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72588","article-title":"Synergistic phase separation of two pathways promotes integrin clustering and nascent adhesion formation","volume":"11","author":"Case","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.trecan.2025.12.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301881120","article-title":"Surface-induced phase separation of reconstituted nascent integrin clusters on lipid membranes","volume":"120","author":"Hsu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.12.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.261723","article-title":"Focal adhesion kinase signaling\u2014tumor vulnerabilities and clinical opportunities","volume":"137","author":"Schlaepfer","year":"2024","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0045","doi-asserted-by":"crossref","first-page":"21526","DOI":"10.1074\/jbc.M110.129999","article-title":"Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation","volume":"285","author":"Lim","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2025.12.008_bb0050","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.12.008_bb0055","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1158\/2767-9764.CRC-24-0382","article-title":"Nuclear focal adhesion kinase protects against cisplatin stress in ovarian carcinoma","volume":"4","author":"Zhang","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.trecan.2025.12.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114297","article-title":"FAK regulates tension transmission to the nucleus and endothelial transcriptome independent of kinase activity","volume":"43","author":"Akhter","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.12.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan8355","article-title":"IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks","volume":"10","author":"Serrels","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.trecan.2025.12.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117065119","article-title":"Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis","volume":"119","author":"Ozmadenci","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.12.008_bb0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/372786a0","article-title":"Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase","volume":"372","author":"Schlaepfer","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.12.008_bb0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/377539a0","article-title":"Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice","volume":"377","author":"Ilic","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.12.008_bb0085","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1074\/jbc.M109.064212","article-title":"Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival","volume":"285","author":"Lim","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2025.12.008_bb0090","doi-asserted-by":"crossref","first-page":"ar64","DOI":"10.1091\/mbc.E24-12-0562","article-title":"Inducible FAK loss but not FAK inhibition in endothelial cells of PYK2-null mice activates p53 tumor suppressor to prevent tumor growth","volume":"36","author":"Chen","year":"2025","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.trecan.2025.12.008_bb0095","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0140-6736(93)92881-S","article-title":"Expression of focal adhesion kinase gene and invasive cancer","volume":"342","author":"Weiner","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.12.008_bb0100","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1038\/sj.onc.1202957","article-title":"Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells","volume":"18","author":"Agochiya","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2025.12.008_bb0105","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND\u2014a double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.12.008_bb0115","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41591-025-03763-y","article-title":"Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial","volume":"31","author":"Banerjee","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0120","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of treatment in patients with recurrent low grade serous ovarian cancer","volume":"35","author":"Grisham","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.trecan.2025.12.008_bb0130","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47327","article-title":"FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy","volume":"8","author":"Diaz Osterman","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.trecan.2025.12.008_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111120","article-title":"The PTK2B gene is associated with obesity, adiposity, and leptin levels in children and adolescents","volume":"27","author":"Prida","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.trecan.2025.12.008_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202105696","article-title":"Mouse modeling dissecting macrophage-breast cancer communication uncovered roles of PYK2 in macrophage recruitment and breast tumorigenesis","volume":"9","author":"Muller","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0145","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1158\/2159-8290.CD-24-1712","article-title":"The immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer","volume":"15","author":"Xie","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.12.008_bb0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tcb.2023.07.006","article-title":"PYK2, a hub of signaling networks in breast cancer progression","volume":"34","author":"Gil-Henn","year":"2024","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2021.749001","article-title":"The non-receptor tyrosine kinase Pyk2 in brain function and neurological and psychiatric diseases","volume":"13","author":"de Pins","year":"2021","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/pharmaceutics17050549","article-title":"Drug combinations targeting FAK and MEK overcomes tumor heterogeneity in glioblastoma","volume":"17","author":"Furqan","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.trecan.2025.12.008_bb0165","article-title":"Combined inhibition of focal adhesion kinase and RAF\/MEK elicits synergistic inhibition of melanoma growth and reduces metastases","volume":"6","author":"Almazan","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0170","doi-asserted-by":"crossref","first-page":"13467","DOI":"10.3390\/ijms241713467","article-title":"Pyk2\/FAK signaling is upregulated in recurrent glioblastoma tumors in a C57BL\/6\/GL261 glioma implantation model","volume":"24","author":"Ortiz Rivera","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0175","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.052634","article-title":"FAK modulates glioblastoma stem cell energetics via regulation of glycolysis and glutamine oxidation","volume":"18","author":"Masalmeh","year":"2025","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.trecan.2025.12.008_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116913","article-title":"Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: structural insights and therapeutic potential","volume":"279","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.trecan.2025.12.008_bb0185","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/s41467-025-57196-9","article-title":"Structure-based discovery of hydrocarbon-stapled paxillin peptides that block FAK scaffolding in cancer","volume":"16","author":"Reyes","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.12.008_bb0190","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12964-025-02203-1","article-title":"Targeting the hydrophobic pockets of FAK\/PYK2 FAT domain: a highly effective inhibitory strategy suppressing tumor growth and eliminating metastasis","volume":"23","author":"Christoforou","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.trecan.2025.12.008_bb0195","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41556-025-01697-8","article-title":"Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer","volume":"27","author":"Al-Hilal","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109017","article-title":"Structure-guided design of a potent focal adhesion kinase (FAK) degrader via ternary complex modeling and molecular dynamics simulation","volume":"165","author":"Liu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.trecan.2025.12.008_bb0205","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1039\/D5MD00095E","article-title":"Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation","volume":"16","author":"Pogash","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.trecan.2025.12.008_bb0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2024.04.010","article-title":"Preclinical in vitro and in vivo activity of the RAF\/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas","volume":"187","author":"Demirkiran","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0215","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.12.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2402","article-title":"Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy","volume":"16","author":"Liu","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/gutjnl-2018-317424","article-title":"Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion","volume":"69","author":"Jiang","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.trecan.2025.12.008_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","article-title":"FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer","volume":"73","author":"Canel","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.trecan.2025.12.008_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.33696\/cancerimmunol.7.109","article-title":"Targeting FAK to potentiate immune checkpoint therapy in solid tumors","volume":"7","author":"Stanley","year":"2025","journal-title":"J. Cancer Immunol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0240","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1535-7163.MCT-17-0561","article-title":"Wnt\/beta-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2025.12.008_bb0245","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2025.12.008_bb0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","article-title":"The RAS-MEK-ERK pathway in low-grade serous ovarian cancer","volume":"200","author":"Stover","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0255","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/ijgc-2024-005305","article-title":"Molecular changes driving low-grade serous ovarian cancer and implications for treatment","volume":"34","author":"Kelliher","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.trecan.2025.12.008_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-023-00471-6","article-title":"Targeting focal adhesion kinase boosts immune response in KRAS\/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment","volume":"13","author":"Qiao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0265","article-title":"Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70210","article-title":"Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer","volume":"13","author":"Hartwich","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0275","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2025.02.001","article-title":"FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma","volume":"43","author":"Lubrano","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.12.008_bb0280","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012010","article-title":"FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer","volume":"12","author":"Zaghdoudi","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0285","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/path.5833","article-title":"Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth","volume":"256","author":"Newport","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0290","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/0008-5472.CAN-20-3807","article-title":"Suppression of endothelial cell FAK expression reduces pancreatic ductal adenocarcinoma metastasis after gemcitabine treatment","volume":"82","author":"Roy-Luzarraga","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.12.008_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122542","article-title":"FAK, vinculin, and talin control mechanosensitive YAP nuclear localization","volume":"308","author":"Holland","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.trecan.2025.12.008_bb0300","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3390\/ijms23041998","article-title":"New insights on the nuclear functions and targeting of FAK in cancer","volume":"23","author":"Pomella","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0305","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1016\/j.bmcl.2016.10.092","article-title":"Selectivity switch between FAK and Pyk2: macrocyclization of FAK inhibitors improves Pyk2 potency","volume":"26","author":"Farand","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.trecan.2025.12.008_bb0310","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4161\/cbt.9.10.11434","article-title":"PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments","volume":"9","author":"Tanjoni","year":"2010","journal-title":"Cancer Biol. Therapy"},{"key":"10.1016\/j.trecan.2025.12.008_bb0315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00109-018-1725-7","article-title":"The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma","volume":"97","author":"Laszlo","year":"2019","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2025.09.376","article-title":"Focal adhesion kinase-dependent reprogramming of IFN-gamma signaling through PYK2 coinhibition sensitizes melanoma to immune checkpoint blockade","author":"Mizuno","year":"2025","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0325","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.trecan.2023.07.006","article-title":"Beyond matrix stiffness: targeting force-induced cancer drug resistance","volume":"9","author":"Kalli","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2025.12.008_bb0330","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41568-024-00745-z","article-title":"Compressive stresses in cancer: characterization and implications for tumour progression and treatment","volume":"24","author":"Linke","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.12.008_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117882","article-title":"Focal adhesion kinase inhibitors in fibrotic diseases therapy: development and therapeutic potential","volume":"296","author":"Gan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.trecan.2025.12.008_bb0340","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-021-22602-5","article-title":"Force-FAK signaling coupling at individual focal adhesions coordinates mechanosensing and microtissue repair","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.12.008_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw6425","article-title":"Mechanochemical waves in focal adhesions during cell migration","volume":"11","author":"Fernandez-Yague","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2025.12.008_bb0350","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1073\/pnas.1820567116","article-title":"Structural and mechanistic insights into mechanoactivation of focal adhesion kinase","volume":"116","author":"Bauer","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.12.008_bb0355","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259089","article-title":"New insights into FAK structure and function in focal adhesions","volume":"135","author":"Le Coq","year":"2022","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.trecan.2025.12.008_bb0360","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41467-021-24009-8","article-title":"Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance","volume":"12","author":"Pietila","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.12.008_bb0365","article-title":"Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses","volume":"28","author":"Zhang","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.trecan.2025.12.008_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0375","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jid.2018.04.034","article-title":"Controlled delivery of a focal adhesion kinase inhibitor results in accelerated wound closure with decreased scar formation","volume":"138","author":"Ma","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0380","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1038\/s41467-021-25410-z","article-title":"Disrupting biological sensors of force promotes tissue regeneration in large organisms","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.12.008_bb0385","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj9152","article-title":"Disrupting mechanotransduction decreases fibrosis and contracture in split-thickness skin grafting","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.12.008_bb0390","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i33.105466","article-title":"Focal adhesion kinase: a promising regulator of colitis-associated healing","volume":"31","author":"Malek","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.trecan.2025.12.008_bb0395","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41419-021-03481-6","article-title":"Mechanical stretch promotes hypertrophic scar formation through mechanically activated cation channel Piezo1","volume":"12","author":"He","year":"2021","journal-title":"Cell Death Dis."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325003164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325003164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:52:35Z","timestamp":1776181955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325003164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2405803325003164"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.12.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disarming cancer resistance: FAK as a therapeutic target","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}